EUCTR2007-001161-14-PL进行中（未招募）不适用
A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris. - CARE MS-I
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 525
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosis of MS and cranial MRI scan demonstrating white matter
- •lesions attributable to MS within 5 years
- •Onset of MS symptoms within 5 years
- •EDSS score 0.0 to 3.0
- •=2 MS attacks within 24 months, with =1 attack within 12 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 525
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Received prior therapy for MS other than corticosteroids
- •Exposure to immunosuppressive or immunomodulatory agents other
- •than systemic corticosteroid treatment
- •Received treatment with a monoclonal antibody for any reason
- •Previous treatment with any investigational drug (i.e. medication that
- •is not approved at any dose for any indication)
- •Has any progressive form of MS
- •Any disability acquired from trauma or another illness that could
- •interfere with evaluation of disability due to MS
- •Major systemic disease that cannot be treated or adequately controlled
- •Active infection or high risk for infection
- •Autoimmune disorder (other than MS)
- •Impaired hepatic or renal function
- •History of malignancy, except basal skin cell carcinoma
- •Medical, psychiatric, cognitive, or other conditions that compromise the
- •patient's ability to understand the patient information, to give informed
- •consent, to comply with the trial protocol, or to complete the study
- •Known bleeding disorder
- •Of childbearing potential with a positive serum pregnancy test,
- •pregnant or lactating
- •Current participation in another clinical study
- •Previous hypersensitivity reaction to any immunoglobulin product
- •Known allergy or intolerance to interferon beta, human albumin, or
- •Intolerance of pulsed corticosteroids, especially a history of steroid
- •Inability to self-administer subcutaneous (SC) injections or receive SC
- •injections from caregiver
- •Inability to undergo MRI with gadolinium administration
- •Unwilling to use a reliable and acceptable contraceptive method
- •throughout the study period (fertile patients only)
研究者
相似试验
进行中（未招募）
不适用
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple SclerosisEUCTR2007-001161-14-SEGenzyme Corporation525
进行中（未招募）
不适用
A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris. - CARE MS-IRelapsing Remitting Multiple SclerosisMedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2007-001161-14-GBGenzyme Corporation525
进行中（未招募）
3 期
Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study OneACTRN12608000435381Genzyme Corporation581
进行中（未招募）
不适用
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple SclerosisRelapsing Remitting Multiple SclerosisMedDRA version: 14.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2007-001161-14-DEGenzyme Corporation525
进行中（未招募）
1 期
A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris. - CARE MS-IRelapsing Remitting Multiple SclerosisMedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2007-001161-14-FRGenzyme Corporation525